...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Trials and statistics, next steps

Just one more comment......the CHF reduction was most pronounced in the CKD population. Still a CHF benefit in non-CKD patients, but a much more robust reduction in CKD patients.

BDAZ

Share
New Message
Please login to post a reply